MDimune Inc. focuses on advancing therapeutics through its innovative BioDrone™ platform technology, which utilizes cell-derived vesicles (CDVs) for targeted drug delivery. This approach aims to enhance the precision and effectiveness of treatments for various debilitating diseases, including cancer and central nervous system disorders. By leveraging the unique properties of CDVs, MDimune seeks to revolutionize the way drugs are delivered, ensuring that therapies are not only more effective but also safer for patients.

In addition to its BioDrone™ technology, MDimune is actively engaged in global collaborations and partnerships to further its research and development efforts. The company emphasizes a strategy known as PIDO (Platform Inside Development Outside), which facilitates joint pipeline development and risk management through collaborative initiatives. This commitment to open innovation and bio-customization positions MDimune as a forward-thinking player in the field of gene therapy, including mRNA, siRNA, and miRNA applications, ultimately aiming to provide groundbreaking solutions in human therapeutics.

South Korea

MDimune - The ultimate goal of MDimune Inc. is to provide an innovative platform technology that can revolutionize the paradigm of human therapeutics by achieving target-specific delivery of effective drugs. The precision of this novel technology will enable safer and more effective treatments of many debilitating human diseases and bring hope to patients.

MDimune

Company Details